A5035969103- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Bladder and Urothelial Cancer Treatments
- Hormonal and reproductive studies
- Cancer, Lipids, and Metabolism
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Radiomics and Machine Learning in Medical Imaging
- Statistical Methods in Clinical Trials
- Urinary Bladder and Prostate Research
- Renal cell carcinoma treatment
- Effects of Radiation Exposure
- Radiopharmaceutical Chemistry and Applications
- Brain Metastases and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Advances in Oncology and Radiotherapy
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Urologic and reproductive health conditions
- Radiation Therapy and Dosimetry
- Glioma Diagnosis and Treatment
- Surgical site infection prevention
- Occupational and environmental lung diseases
- Genetic Neurodegenerative Diseases
University of Geneva
2021-2025
Institut Bergonié
2025
University Hospital of Geneva
2019-2024
Réseau Fribourgeois de Santé Mentale
2023-2024
University of Fribourg
2024
Fribourg Development Agency
2022-2023
Hôpital Beau-Séjour
2020-2022
Background and purposeOligometastatic prostate cancer is a new emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective small phase 2 large difference across centers. Pending results ongoing trials, there clear need for more consistent indications radiotherapy practices.Material methodsA European Society...
Background/Aim: KRAS mutation is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC). It associated with a poor prognosis without available targeted therapy. Treatment options for NSCLC have been recently enriched by development of immune checkpoint inhibitors (ICIs), and data about their efficacy patients KRAS-mutant are discordant. This study assessed routine ICIs NSCLC. Patients Methods: All stage IV treated our institution from January 2016 to...
To assess in a prospective, multicenter, single-arm phase I/II study the early safety and efficacy profile of single fraction urethra-sparing stereotactic body radiotherapy (SBRT) for men with localized prostate cancer.
PurposeClinical target volume (CTV) delineation for pelvic lymph nodes in prostate cancer is currently based on 3 consensus guidelines with some inherent discrepancies. To improve the reproducibility nodal delineation, Francophone Group of Urological Radiotherapy (Groupe de Radiothérapie Urologique [GFRU]) worked toward proposing an easily applicable, reproducible, and practice-validated contouring guideline CTV.Methods MaterialsThe CTV data sets a high-risk node-negative clinical case...
Background/Objectives: To analyze the predictive value of apparent diffusion coefficient (ADC) in patients with prostate cancer (PCa) treated radiotherapy (RT) and androgen deprivation therapy (ADT). Methods: Retrospective study high-risk, very or unfavorable intermediate-risk PCa who received RT ADT between 2008 2019 underwent multiparametric magnetic resonance imaging mpMRI) at 6 months post-RT. Differences ADC values were compared without progression and/or local recurrence. Receiver...
Erectile dysfunction (ED) is a common side effect after prostate cancer stereotactic body radiation therapy (SBRT). We aimed to assess the correlation between dose penile bulb (PB), internal pudendal arteries (IPA), and crura with development of ED ultrahypofractionation as part phase 2 clinical trial urethra-sparing SBRT.